Patents Issued in May 30, 2019
  • PRINS REACTION AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF HALICHONDRIN MACROLIDES AND ANALOGS THEREOF
    Publication number: 20190161495
    Abstract: The invention provides methods for the synthesis of a halichondrin macrolides or analogs thereof through a cyclization reaction strategy. The strategy of the present invention involves subjecting an intermediate to Prins reaction conditions to afford a macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides or analogs thereof and methods for preparing the same.
    Type: Application
    Filed: June 30, 2017
    Publication date: May 30, 2019
    Inventors: Charles E. CHASE, Hyeong-Wook CHOI, Atsushi ENDO, Francis G. FANG, Dae-Shik KIM
  • HYDROXYESTER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Publication number: 20190161496
    Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R13, Ra, Rb, A and n are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.
    Type: Application
    Filed: January 15, 2019
    Publication date: May 30, 2019
    Inventors: Zoltán SZLÁVIK, Andràs Kotschy, Maïa Chanrion, Didier Demarles, Olivier Geneste, James Edward Paul Davidson, James Brooke Murray, Szabolcs Sipos, Attila Paczal, Balázs BÁLINT
  • SPECIFICALLY SUBSTITUTED BENZOFURO- AND BENZOTHIENOQUINOLINES FOR ORGANIC LIGHT EMITTING DIODES
    Publication number: 20190161497
    Abstract: Specifically substituted benzofuro- and benzothienoquinolines and their use in electronic devices, especially electroluminescent devices. When used as charge transport material, charge blocker material and/or host material in electroluminescent devices, the specifically substituted benzofuro- and benzothienoquinolines may provide improved efficiency, stability, manufacturability, or spectral characteristics of electroluminescent devices and reduced driving voltage of electroluminescent devices.
    Type: Application
    Filed: June 13, 2017
    Publication date: May 30, 2019
    Applicant: IDEMITSU KOSAN CO., LTD.
    Inventors: Yuichi NISHIMAE, Michelle GROARKE, Heinz WOLLEB, Annemarie WOLLEB, Yuki NAKANO, Hideaki NAGASHIMA, Tasuku HAKETA, Masahiro KAWAMURA, Takushi SHIOMI
  • POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4
    Publication number: 20190161498
    Abstract: Disclosed herein are tricyclic compounds, including pyrimido[4?,5?:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3?,2?:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2?,3?:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3?,2?:4,5]furo[3,2-d]pyrimidin-4-amine, and pyrimido[4?,5?:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Application
    Filed: January 29, 2019
    Publication date: May 30, 2019
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Sean Bollinger, James C. Tarr, Paul Spearing, Julie L. Engers, Madeline Long, Thomas M. Bridges
  • PESTICIDALLY ACTIVE 1,2,4-TRIAZOLE DERIVATIVES
    Publication number: 20190161499
    Abstract: The present invention relates to 1,2,4-triazole derivatives, to processes for preparing them, to intermediates for preparing them, to pesticidli, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising those derivatives and to methods of using them to combat and control pests such as insect, acarine, mollusc and nematode pests.
    Type: Application
    Filed: December 8, 2016
    Publication date: May 30, 2019
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Andrew Edmunds, Jürgen Harry Schaetzer, Aurelien Bigot, Sebastian Rendler, André Jeanguenat
  • QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20190161500
    Abstract: The invention includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: January 31, 2019
    Publication date: May 30, 2019
    Applicant: Array BioPharma Inc.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT
    Publication number: 20190161501
    Abstract: Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(?O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 27, 2017
    Publication date: May 30, 2019
    Applicant: Shionogi & Co., Ltd.
    Inventors: Hiroyuki TOBINAGA, Koji MASUDA, Satoshi KASUYA, Masanao INAGAKI, Mitsuhiro YONEHARA, Manami MASUDA
  • 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS
    Publication number: 20190161502
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, useful as a BACE1 inhibitor.
    Type: Application
    Filed: August 18, 2017
    Publication date: May 30, 2019
    Inventors: Steven James Green, Erik James Hembre, II, Dustin James Mergott
  • XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME
    Publication number: 20190161503
    Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.
    Type: Application
    Filed: July 27, 2017
    Publication date: May 30, 2019
    Applicants: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN, FORSCHUNGSVERBUND BERLIN E.V.
    Inventors: Michael BADER, Edgar SPECKER, Susann MATTHES, Anja SCHÜTZ, Keven MALLOW, Maik GROHMANN, Marc NAZARÉ
  • CARBENE COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICES
    Publication number: 20190161504
    Abstract: A compound selected from the group consisting of Formula I, Formula II, and Formula III, wherein ring A, ring B, and ring C are independently a five-membered or six-membered, carbocyclic or heterocyclic ring, each of which is optionally aromatic; ring W of Formula I is a 6-membered heterocyclic ring, and ring W of Formula II or Formula III is a 5-membered or 6-membered heterocyclic ring; L is a monodentate ligand with a metal coordinating member selected from the group consisting of C, N, O, S, and P; and M is a metal selected from the group consisting of Cu, Au, and Ag.
    Type: Application
    Filed: November 15, 2018
    Publication date: May 30, 2019
    Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Mark E. THOMPSON, Peter I. DJUROVICH, Rasha HAMZE, Shuyang SHI, Moon Chul JUNG
  • CONTINUOUS METHOD FOR PRODUCING GRIGNARD ADDUCTS AND A DEVICE FOR CARRYING OUT SAME
    Publication number: 20190161505
    Abstract: The invention relates to a continuous method for the production of Grignard adducts, in which the magnesium chips are activated mechanically in situ. Furthermore, the invention relates to a device for implementation of the method according to the invention.
    Type: Application
    Filed: March 29, 2017
    Publication date: May 30, 2019
    Applicant: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E. V.
    Inventors: Gabriele MENGES-FLANAGAN, Christian HOFMANN
  • SILANE MIXTURES AND PROCESSES FOR PREPARATION THEREOF
    Publication number: 20190161506
    Abstract: The invention relates to silane mixtures comprising a silane of the formula I (R1)y(R2)3-ySi—R3—(S—R4)n—S—R5??(I) and a silane of the formula II (R1)y(R2)3-ySi—R3—(S—R4)z—S—R3—Si(R1)y(R2)3-y??(II) where the molar ratio of silane of the formula I to silane of the formula II is 20:80-90:10. The silane mixture according to the invention can be prepared by mixing the silanes of the formula I and silanes of the formula II.
    Type: Application
    Filed: November 27, 2018
    Publication date: May 30, 2019
    Applicant: Evonik Degussa GmbH
    Inventors: Caren ROEBEN, Ralph MOSER, Alexander KOEPFER, Stefanie MAYER, Andre HASSE, Frank FORSTER
  • TITANIUM-CONTAINING FILM FORMING COMPOSITIONS FOR VAPOR DEPOSITION OF TITANIUM-CONTAINING FILMS
    Publication number: 20190161507
    Abstract: Titanium-containing film forming compositions comprising titanium halide-containing precursors are disclosed. Also disclosed are methods of synthesizing and using the disclosed precursors to deposit Titanium-containing films on one or more substrates via vapor deposition processes.
    Type: Application
    Filed: May 1, 2018
    Publication date: May 30, 2019
    Inventors: Antonio SANCHEZ, Jean-Marc GIRARD, Grigory NIKIFOROV, Nicolas BLASCO
  • HIGHLY ISOSELECTIVE CATALYST FOR ALKENE HYDROFORMYLATION
    Publication number: 20190161508
    Abstract: Ligands for use with catalyst compositions used in hydroformylation reactions are described herein. The ligands are used with various octofluorotoluene or hydrocarbon solvents and achieve an increase in isoselectivity with an increase in temperature, an increase in TON with an increase in temperature, and/or will show isoselectivity that is surprisingly high in comparison to the hydroformylation reactions using common solvents.
    Type: Application
    Filed: October 29, 2018
    Publication date: May 30, 2019
    Applicant: Eastman Chemical Company
    Inventors: Leo Iu, Matthew Clarke, Kevin John Fontenot, Mesfin Ejerssa Janka
  • ZWITTERION COMPOUNDS AND PHOTORESISTS COMPRISING SAME
    Publication number: 20190161509
    Abstract: New Te-zwitterion compounds are provided, including photoactive tellurium salt compounds useful for Extreme Ultraviolet Lithography.
    Type: Application
    Filed: November 29, 2018
    Publication date: May 30, 2019
    Inventors: Emad Aqad, James F. Cameron, James W. Thackeray
  • METAL COMPLEXES FOR USE AS EMITTERS IN ORGANIC ELECTROLUMINESCENCE DEVICES
    Publication number: 20190161510
    Abstract: The present invention relates to metal complexes and electronic devices, in particular organic electroluminescent devices containing said metal complexes.
    Type: Application
    Filed: July 20, 2017
    Publication date: May 30, 2019
    Applicant: Merck Patent GmbH
    Inventors: Philipp Stoessel, Christian Ehrenreich
  • METHOD FOR SEPARATION OF ACIDS AND SUGARS TO REDUCE ENERGY CONSUMPTION
    Publication number: 20190161511
    Abstract: The present disclosure relates to a method for separating sugars and acids with reduced energy consumption, including a step of diffusively dialyzing a first acid hydrolysate obtained by saccharifying biomass with an acid solution, thereby preparing a second acid hydrolysate wherein the concentration of the acid solution contained in the acid hydrolysate is decreased; and a step of electrolyzing the second acid hydrolysate, thereby separating sugars from the acid solution, which is advantageous in that less energy is consumed, the separated acid solution can be recycled directly without further treatment due to high concentration and loss of sugars can be minimized.
    Type: Application
    Filed: November 21, 2018
    Publication date: May 30, 2019
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Youngsoon UM, Kyung Min LEE, Sun-Mi LEE, Hong Gon KIM, Gyeongtaek GONG
  • GLYCEROGLYCOLIPID ANTIGEN OF MYCOPLASMA PNEUMONIAE
    Publication number: 20190161512
    Abstract: The present invention provides a novel glyceroglycolipid produced by Mycoplasma pneumoniae. The glyceroglycolipid can be used as a diagnostic marker for a disease caused by Mycoplasma pneumoniae.
    Type: Application
    Filed: December 27, 2018
    Publication date: May 30, 2019
    Applicant: M BIO TECHNOLOGY INC.
    Inventors: Kazuhiro MATSUDA, Yuko SHINGU
  • SYNTHESIS OF THIOLATED OLIGONUCLEOTIDES WITHOUT A CAPPING STEP
    Publication number: 20190161513
    Abstract: The invention herein describes a synthetic method for preparing thiolated oligonucleotides without needing a capping step, as the sulfurization agent caps the unreacted 5?-OH groups.
    Type: Application
    Filed: June 22, 2017
    Publication date: May 30, 2019
    Inventors: Xianglin Shi, Jimin Yang, William F. Kiesman, Yannick Fillon
  • AZASTEROIDS FOR TREATMENT OF TUBERCULOSIS
    Publication number: 20190161514
    Abstract: The present invention provides a compound having the structure: for use in combination with an anti-tuberculosis drug for treating a subject infected with M. tuberculosis.
    Type: Application
    Filed: April 28, 2017
    Publication date: May 30, 2019
    Applicant: The Research Foundation for the State University of New York
    Inventors: Nicole Sampson, Xinxin Yang, Tianao Yuan
  • MATERIALS AND METHODS FOR DETECTION AND QUANTIFICATION OF BETA-N-METHYLAMINO-L-ALANINE
    Publication number: 20190161515
    Abstract: Provided herein are isotopically labeled reagents, including isotopically labeled small molecules and peptides, that can be used to detect and/or quantify ?-N-methylamino-L-alanine (BMAA) in a sample. The reagents can be used as stable isotope labeled standards in analytical methods, including in conjunction with mass spectrometry, to detect and/or quantify BMAA in a sample, such as a protein sample from a subject.
    Type: Application
    Filed: July 31, 2017
    Publication date: May 30, 2019
    Inventors: David C. Muddiman, Philip L. Loziuk, Joshua G. Pierce, Gavin Williams, Yasamin Moazami
  • PROTEASOME INHIBITORS
    Publication number: 20190161516
    Abstract: Unique epoxyketone compounds useful for inhibiting a proteasome in a cell, pharmaceutical compositions and methods of their use are provided herein.
    Type: Application
    Filed: June 28, 2018
    Publication date: May 30, 2019
    Inventor: Kyung Bo Kim
  • NOVEL PEPTIDE AND USE THEREOF
    Publication number: 20190161517
    Abstract: The present invention provides a peptide consisting of the amino acid sequence of SEQ ID NO:1 or the amino acid sequence of SEQ ID NO:2, or a pharmaceutically acceptable salt thereof and a use thereof. The present invention can inhibit the entry of beta-amyloid into the brain. In addition, the present invention can be applied more easily with respect to the suppression of the intracerebral action of beta-amyloid and thus is advantageous in having excellent applicability.
    Type: Application
    Filed: March 24, 2017
    Publication date: May 30, 2019
    Inventors: Hae Jin KIM, Eun Joung MOON, Duk Soon HWANG
  • PHARMACEUTICAL COMPOSITION AND THE USE THEROF IN THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20190161518
    Abstract: The present invention relates to compounds comprising formula I: Amino Acid Sequence-(L)n-DMARD wherein the amino acid sequence comprises QKRAAYDQYGHAAFE-NH2 (SEQ ID NO: 1), DMARD is a disease modifying antirheumatic agent, L is a linker unit; —is a covalent bond and n is 0 or 1 and methods of using the compound for treatment of autoimmune diseases. In a preferred embodiment the DMARD is selected from Chloroquine and Hydroxychloroquine.
    Type: Application
    Filed: May 18, 2017
    Publication date: May 30, 2019
    Applicant: SINGAPORE HEALTH SERVICES PTE. LTD.
    Inventor: Salvatore ALBANI
  • ENGINEERED INFLUENZA ANTIGENIC POLYPEPTIDES AND IMMUNOGENIC COMPOSITIONS THEREOF
    Publication number: 20190161519
    Abstract: The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered influenza B hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple influenza B viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.
    Type: Application
    Filed: June 2, 2017
    Publication date: May 30, 2019
    Inventors: Tod Strugnell, Eliud Oloo
  • MSA2 AFFINITY-ENHANCED BIOTIN-BINDING CHIMERIC ANTIGEN RECEPTOR (CAR)
    Publication number: 20190161520
    Abstract: A chimeric antigen receptor is disclosed that includes: (a) an extracellular high affinity streptavidin;(b) a hinge domain from CD8; (c) a CD28 transmembrane domain; (d) an intracellular 4-1BB and/or CD28 signaling domain; and (e) an intracellular CD3 zeta signaling domain, wherein (a)-(e) are in N-terminal to C-terminal order. Nucleic acids encoding this chimeric antigen receptor, and T and natural killer (NK) cells transformed with this chimeric antigen receptor are also disclosed. The use of this chimeric antigen receptor for the treatment of tumors is also disclosed.
    Type: Application
    Filed: November 7, 2018
    Publication date: May 30, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventor: Jason Lohmueller
  • ANTIBODY BINDING NANOFIBRILS
    Publication number: 20190161521
    Abstract: The present embodiments relate to antibody binding nanofibrils obtainable by co-fibrillation of carrier proteins and carrier-Z fusion proteins at a molar ratio selected within an interval of from 1:0.20 to :0.90. The antibody binding nanofibrils have extremely high antibody binding capacity and can thereby be used in various applications, such as antibody purification, and detection of biomarkers in point of care or laboratory diagnosis applications.
    Type: Application
    Filed: May 8, 2017
    Publication date: May 30, 2019
    Inventors: Torleif Härd, Mats Sandgren, Benjamin Schmuck
  • ARTICLES COMPRISING A SILK POLYPEPTIDE FOR ANTIGEN DELIVERY
    Publication number: 20190161522
    Abstract: The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.
    Type: Application
    Filed: June 13, 2017
    Publication date: May 30, 2019
    Inventors: Lin ROMER, Ute SLOTTA, Julia ENGERT, Gerhard Winter, Matthias Lucke, Thomas Scheibel
  • METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES
    Publication number: 20190161523
    Abstract: Compositions, formulations, and kits comprising chlorotoxin conjugate compounds are provided, including native and modified variants of chlorotoxin peptide conjugated to reporter molecules including fluorescent dyes or conjugated to cytotoxic agents. Dosing and pharmacokinetic profiles for therapeutic and diagnostic applications using chlorotoxin conjugate compounds are provided.
    Type: Application
    Filed: April 12, 2017
    Publication date: May 30, 2019
    Inventors: Dennis M. Miller, Kelly Byrnes-Blake
  • NOVEL ALPHA-1-MICROGLOBULIN DERIVED PROTEINS AND THEIR USE
    Publication number: 20190161524
    Abstract: This invention relates to an alpha-1-microglobulin derived protein for medical use.
    Type: Application
    Filed: March 17, 2017
    Publication date: May 30, 2019
    Applicant: A1 M Pharma AB
    Inventors: Lena Webster ROSENLÖF, Anneli Edström HÄGERWALL, Bo AKERSTRÖM
  • Method for treating Alzheimer's disease and method for downregulating protein aggregation in brain
    Publication number: 20190161525
    Abstract: A method for treating Alzheimer's disease and a method for downregulating protein aggregation in brain are disclosed, which respectively comprises: administering a zinc finger-like peptide to a subject in need thereof, wherein the zinc finger-like peptide comprises an amino acid sequence of RRSSSCK (SEQ ID NO: 1).
    Type: Application
    Filed: March 6, 2018
    Publication date: May 30, 2019
    Inventors: Nan-Shan CHANG, Yu-Min KUO
  • Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
    Publication number: 20190161526
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: December 31, 2018
    Publication date: May 30, 2019
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • PEPTIDES AND COMPOSITIONS FOR TREATMENT OF JOINT DAMAGE
    Publication number: 20190161527
    Abstract: The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
    Type: Application
    Filed: February 7, 2019
    Publication date: May 30, 2019
    Inventors: Kristen JOHNSON, Jian SHI
  • CLAUDIN-6 PEPTIDES
    Publication number: 20190161528
    Abstract: The present invention relates to novel peptides derived from Claudin-6 (CLDN6), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Application
    Filed: April 28, 2017
    Publication date: May 30, 2019
    Inventors: Alex POWLESLAND, Mei SUN
  • COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES
    Publication number: 20190161529
    Abstract: Compositions and methods are provided for modulating the activity of cells using engineered receptors, polynucleotide encoded engineered receptors, and gene therapy vectors comprising polynucleotides encoding engineered receptors. These compositions and methods find particular use in modulating the activity of neurons, for example in the treatment of disease or in the study of neuronal circuits.
    Type: Application
    Filed: November 27, 2018
    Publication date: May 30, 2019
    Inventors: Kenneth P. GREENBERG, Orion KEIFER, Jr., Stefanie MAKINSON, Anthony LAU
  • CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS
    Publication number: 20190161530
    Abstract: The invention provides improved compositions for adoptive immune effector cell therapies for treatment, prevention, or amelioration of numerous conditions including, but not limited to cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency.
    Type: Application
    Filed: April 7, 2017
    Publication date: May 30, 2019
    Applicant: bluebird bio, Inc.
    Inventors: Michael T. CERTO, Wai-Hang LEUNG
  • Cell
    Publication number: 20190161531
    Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.
    Type: Application
    Filed: December 6, 2018
    Publication date: May 30, 2019
    Inventors: Martin Pulé, Shaun Cordoba, Shimobi Onuoha, Simon Thomas
  • HCMV ENTRY INHIBITORS
    Publication number: 20190161532
    Abstract: Subject matter of the present invention is a soluble PDGFR-alpha-Fc chimera or a PDGFR-alpha derived peptide or an anti-PDGFR-alpha antibody or a PDGFR-alpha antibody fragment or anti-PDGFR-alpha non-Ig scaffold for inhibiting HCMV entry for use in a method of treatment in a subject that has been infected by HCMV or for use in a method of prophylaxis of HCMV infection in a subject that has not yet been infected by HCMV.
    Type: Application
    Filed: June 27, 2017
    Publication date: May 30, 2019
    Applicant: AiCuris Anti-Infective Cures GmbH
    Inventors: Christian SINZGER, Cora STEGMANN, Kerstin LAIB SAMPAIO, Barbara ADLER
  • Process for Preparing Immunoglobulin Compositions
    Publication number: 20190161533
    Abstract: A process for the preparation of pharmaceutically acceptable immunoglobulin compositions from plasma-derived immunoglobulin fractions which allows the parallel preparation of immunoglobulin compositions enriched in IgG, IgM and IgA. In this process, immunoglobulin contained in Cohn fraction I/II/III or Kistler Nitschmann fraction A+I is resolubilized at conductivities of at least 1 mS/cm, and following removal of contaminating protein the resolubilized immunoglobulin is subjected to anion exchange chromatography to obtain IgG- and IgM/IgA-enriched immunoglobulin compositions. The IgG-enriched immunoglobulin composition is further subjected to treatment with a cation exchange material to obtain an immunoglobulin composition having a reduced properdin content.
    Type: Application
    Filed: July 26, 2017
    Publication date: May 30, 2019
    Inventors: Oliver Maneg, Achim Hannappel, Alexander Moehlenkamp-Roettger, Wolfgang Moeller, Dieter Rudnick
  • ANTI-GALACTAN II MONOCLONAL ANTIBODIES TARGETING KLEBSIELLA PNEUMONIAE
    Publication number: 20190161534
    Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
    Type: Application
    Filed: August 11, 2017
    Publication date: May 30, 2019
    Applicants: ARSANIS Biosciences GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Eszter NAGY, Tim ROLLENSKE, Hedda WARDEMANN
  • COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY
    Publication number: 20190161535
    Abstract: The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating spinal muscular atrophy, comprising administering to a subject an inhibitor of the complement pathway.
    Type: Application
    Filed: May 9, 2017
    Publication date: May 30, 2019
    Inventors: Ted Yednock, Sethu Sankaranarayanan
  • ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS TO TREAT METABOLIC DISORDERS
    Publication number: 20190161536
    Abstract: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.
    Type: Application
    Filed: November 20, 2018
    Publication date: May 30, 2019
    Applicants: President and Fellows of Harvard College, UCB Biopharma SPRL
    Inventors: Gökhan S. Hotamisligil, Mehmet F. Burak, Feyza Engin, Scott B. Widenmaier, Elisabeth Helen Roberts, Adrian Richard Moore, Carl Brendan Doyle, Ralph Adams, Karine Jeannine Madeleine Hervé, Shauna Mhairi Wales, Kerry Louise Tyson
  • SYNTHETIC ANTIBODIES TO BAX AND USES THEREOF
    Publication number: 20190161537
    Abstract: Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.
    Type: Application
    Filed: January 30, 2019
    Publication date: May 30, 2019
    Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Evripidis Gavathiotis, Jonathan R. Lai, Sachdev Sidhu
  • Antibodies Specific to Sonic Hedgehog and Method of Use Thereof
    Publication number: 20190161538
    Abstract: Antibodies that specifically bind to a Sonic Hedgehog (Shh) polypeptide, or an antigen binding fragment thereof, are provided. Also provided are methods of treating an individual for cancer using the Shh polypeptide antibodies. Methods of analyzing a tissue sample for cell-surface expression of a full-length Shh polypeptide are also provided.
    Type: Application
    Filed: June 28, 2017
    Publication date: May 30, 2019
    Applicant: The Regents of the University of California
    Inventors: David M. Jablons, Bhairavi Tolani, Biao He, Etienne Giroux-Leprieur
  • COMBINATION THERAPY
    Publication number: 20190161539
    Abstract: A method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of an anti-N3pGlu Abeta antibody, an anti-Abeta antibody, or an antibody fragment that binds Amyloid beta and is covalently attached to a polyethylene glycol molecule, in combination with an effective amount of an anti-Tau antibody.
    Type: Application
    Filed: August 3, 2017
    Publication date: May 30, 2019
    Inventors: Mansuo Lu Hayashi, Michael Carl Irizarry
  • ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF PREPARING AND USING THE SAME
    Publication number: 20190161540
    Abstract: A method of preparing an antibody suitable for use in a canine is provided. Also provided are caninised antibodies which specifically bind to canine neuronal growth factor (NGF) and neutralise the ability of canine NGF to bind to the p75 or TrkA canine NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in a canine using said antibodies and/or nucleic acids.
    Type: Application
    Filed: June 28, 2018
    Publication date: May 30, 2019
    Applicant: NEXVET AUSTRALIA PTY LTD
    Inventor: David Gearing
  • ANTIBODY FORMULATIONS
    Publication number: 20190161541
    Abstract: The invention provides stable aqueous pharmaceutical formulations comprising a therapeutic antibody, trehalose, a buffer, and optional surfactant, and having a pH in the range of about 5.5 to about 7.0. The invention also provides methods for making such formulations and methods of using such formulations.
    Type: Application
    Filed: July 3, 2018
    Publication date: May 30, 2019
    Inventors: Lan LE, Brian Connolly
  • TREATMENT OF CANCER USING A CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH AN INHIBITOR OF A PRO-M2 MACROPHAGE MOLECULE
    Publication number: 20190161542
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of an antigen, e.g., a solid tumor antigen or antigen expressed on a tumor associated with TAMs and/or MDSCs, by administering a recombinant T cell comprising a CAR binding to said antigen, as described herein, in combination with an inhibitor of a pro-M2 macrophage molecule, e.g., described herein. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: August 1, 2017
    Publication date: May 30, 2019
    Applicants: Novartis AG, The Trusteesof the University of Pennsylvania
    Inventors: Saar Gill, Marco Ruella, Michael Klichinsky
  • MODULATION OF AFUCOSYLATED SPECIES IN A MONOCLONAL ANTIBODY COMPOSITION
    Publication number: 20190161543
    Abstract: Alterations in bioreactor cell culture feeding to an extended or continuous feed following an initial period of no feeding reduces the level of high molecular weight, acid charge, and fragment species of monoclonal antibodies expressed in the culture, and enhances the level of afucosylated species of monoclonal antibodies expressed in the culture. Regular fucose infusions following an initial period of no feed media infusion reduces the level of afucosylated species of monoclonal antibodies expressed in the culture. Cell culture manipulation may be used to modulate the level of species of monoclonal antibodies.
    Type: Application
    Filed: January 5, 2017
    Publication date: May 30, 2019
    Inventors: Marc SANTORO, Kevin John JOSE, Sri MADABHUSHI, Scott GANGLOFF
  • ANTI-HUMAN INTERLEUKIN-17A MONOCLONAL ANTIBODY, AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20190161544
    Abstract: An anti-human IL-17A monoclonal antibody, the preparation method, and the use thereof are provided. The anti-human IL-17A monoclonal antibody can specifically bind to human IL-17A and has a good effect for inhibiting the secretion of inflammatory cytokines, such as IL-6 and the like by means of various cell lines induced by IL-17A, and can be used for preparing drugs for treating diseases involving immune-medicated inflammatory responses.
    Type: Application
    Filed: June 9, 2017
    Publication date: May 30, 2019
    Inventors: Chenghai ZHANG, Lingqiao ZHU, Jinlin GUO, Jie ZHAO, Honghai GAO, Lin MA, Wei DANG, Yan YANG